BBC
Virtus LifeSci Biotech Clinical Trials ETF
1 year +36.7%Assets$39.22MVirtus
Fee0.75%a year
Yield1.4%NA
This year+6.8%
5 years-1.3%a year on average
Components125top 10: 15%
Returns
This year
+6.8%
1 year
+36.7%
3 years, yearly
+32.0%
5 years, yearly
-1.3%
10 years, yearly
+7.6%
The fund's own total return. Volatility 32.7% over one year, 35.2% over three; Sharpe ratio over three years 0.87.
Sectors
Healthcare100.0%
Regions
North America94.5%
Europe Developed4.4%
United Kingdom2.2%
Asia Emerging0.6%
Asset classes
Stock US91.4%
Stock non-US10.3%
Cash0.1%
About the fund
- Issuer
- Virtus
- Since
- 2014-12-16
- Listed on
- NYSE ARCA
- ISIN
- US26923G3011
- Turnover
- 65% a year
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.